- Home
- BRLT vs BCAB Comparison
BRLT vs BCAB Comparison
Compare BRLT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- BCAB
- Stock Information
- Founded
- BRLT 2005
- BCAB 2007
- Country
- BRLT United States
- BCAB United States
- Employees
- BRLT N/A
- BCAB N/A
- Industry
- BRLT Consumer Specialties
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- BRLT Consumer Discretionary
- BCAB Health Care
- Exchange
- BRLT Nasdaq
- BCAB Nasdaq
- Market Cap
- BRLT 22.6M
- BCAB 27.0M
- IPO Year
- BRLT 2021
- BCAB 2020
- Fundamental
- Price
- BRLT $1.46
- BCAB $0.32
- Analyst Decision
- BRLT Hold
- BCAB Buy
- Analyst Count
- BRLT 5
- BCAB 2
- Target Price
- BRLT $2.40
- BCAB $5.00
- AVG Volume (30 Days)
- BRLT 101.1K
- BCAB 959.7K
- Earning Date
- BRLT 03-12-2025
- BCAB 03-25-2025
- Dividend Yield
- BRLT N/A
- BCAB N/A
- EPS Growth
- BRLT N/A
- BCAB N/A
- EPS
- BRLT 0.03
- BCAB N/A
- Revenue
- BRLT $422,161,000.00
- BCAB $11,000,000.00
- Revenue This Year
- BRLT $2.43
- BCAB N/A
- Revenue Next Year
- BRLT $10.40
- BCAB N/A
- P/E Ratio
- BRLT $49.00
- BCAB N/A
- Revenue Growth
- BRLT N/A
- BCAB N/A
- 52 Week Low
- BRLT $1.25
- BCAB $0.24
- 52 Week High
- BRLT $3.21
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- BRLT 48.74
- BCAB 37.21
- Support Level
- BRLT $1.26
- BCAB $0.24
- Resistance Level
- BRLT $1.42
- BCAB $0.36
- Average True Range (ATR)
- BRLT 0.12
- BCAB 0.04
- MACD
- BRLT 0.02
- BCAB 0.01
- Stochastic Oscillator
- BRLT 28.99
- BCAB 45.27
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.